Improve Productivity and Accessibility with Award-winning Human-Centered Design

Enhance your workflow with integrated intelligence.

Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy

Case study by ZEISS Microscopy.

Scientific Solutions

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Did you know that not every sphere is really a round sphere?

ZEISS Metrology Expert Tip.

Conjugate Planes in Microscopy

Knowledge Article from ZEISS.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Save the dates: ZEISS Quality Innovation Summit, October 22-24

Embark on a journey to the future of metrology.

Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy

Understand how RICS can be used to measure diffusion coefficients.

Introducing ZEISS arivis Pro 4.2

ZEISS arivis software enhances custom microscopy image analysis.

Danish obesity success causes recruitment problems in southern Sweden

The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.

Jätteanslag till medicinsk grundforskning – åtta projekt delar på 227 miljoner

Mekanismerna bakom kronisk smärta, en atlas över tarmbarriären och B-cellsminnets outforskade dimensioner är några av de åtta grundforskningsprojekt inom medici...

Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”

The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from AB...

The Swedish innovation model: “There is a paradox”

It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process

MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...

Trender inom life science 2025 – Del 2 AI

Artificiell intelligens blir ännu bättre på att tolka data och mer multimodal. Risker med den nya tekniken diskuteras samtidigt allt mer. Del två i serien med t...

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...